Neurology Specific Literature Search   
 
[home][thesaurus]
    

Enter your terms
above and click
the 'Search' button.
Showing articles 0 to 50 of 246 Next >>

Filter Applied: adverse drug reaction (Click to remove)

Severe Neurological Toxicity of Immune Checkpoint Inhibitors: Growing Spectrum
Ann Neurol 87:659-669, Dubey, D.,et al, 2020

Neuroleptic Malignant Syndrome
NEJM 391:1130-1138, Wijdicks,E.F.M. & Ropper,A.H., 2024

A 59-Year-Old Woman Presenting with Diplopia, Dysarthria, Right-sided Weakness, and Encephalopathy
Neurol 97:e859-e864, Manzano, G.S.,et al, 2021

Severe Neurological Toxicity of Immune Checkpoint Inhibitors: Growing Spectrum
Ann Neurol 87:659-669, Dubey, D.,et al, 2020

Inflammatory Demyelinating Polyneuropathy Versus Leptomeningeal Disease Following Ipilimumab
J Immunother Cancer 6:11, Cafuir, L.,et al, 2018

Neurological, Respiratory, Musculoskeletal, Cardiac and Ocular Side-Effects of Anti-PD-1 Therapy
Eur J Cancer 60:210-225, Zimmer, L.,et al, 2016

Evidence-based Guideline: Intravenous Immunoglobulin in the Treatment of Neuromascular Disorders
Neurol 78:1009-1015, Patwa,H.S.,et al, 2012

Long-Term Course of Demyelinating Neuropathies Occurring During Tumor Necrosis Factor-a-Blocker Therapy
JAMA Neurol 66:490-497, Lozeron, P.,et al, 2009

Monoclonal Antibody Therapies and Neurologic Disorders
Arch Neurol 65:1162-1165, Novack,J.C.,et al., 2008

Botulism in 4 Adults Following Cosmetic Injections With an Unlicensed, Highly Concentrated Botulinum Preparation
JAMA 296:2476-2479,2512, Chertow,D.S.,et al, 2006

Chronic Inflammatory Demyelinating Polyneuropathy
NEJM 352:1343-1356, Koller,H.,et al, 2005

Neuropathy Resembling CIDP in Patients Receiving Tumor Necrosis Factor-a Blockers
Neurol 64:1468-1470, Richez,C.,et al, 2005

Neurologic Adverse Events Associated With Smallpox Vaccination in the United States, 2002-2004
JAMA 294:2744-2750, Sejvar,J.J.,et al, 2005

Adverse Events Reported Following Live, Cold-Adapted, Intranasal Influenza Vaccine
JAMA 294:2720-2725, Izurieta,H.S.,et al, 2005

Intravenous Immunoglobulin in Autoimmune Neuromuscular Diseases
JAMA 291:2367-2375, Dalakas,M.C., 2004

Visual Impairment in Children with Epilepsy Treated with Vigabatrin
Ann Neurol 48:60-64, Gross-Tsur,V. et al, 2000

Intravenous Immunoglobulin Treatment in Neurologic Disorders
Arch Neurol 56:1025-1027,1032, Sorensen,P.S., 1999

Is the Routine Use of Intravenous Immunoglobulin Treatment in Neurologic Disorders Justified?
Arch Neurol 56:1028-1032, Karussis,D.&Abramsky,O., 1999

Intravenous Immunoglobulin in the Treatment of Autoimmune Neuromuscular Diseases:Present Status and Practical Therapeutic Guidelines
Muscle & Nerve 22:1479-1497, Dalakas,M.C., 1999

Procainamide-Induced Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Neurol 50:824-825, Erdem,S.,et al, 1998

Pulse Cyclophosphamide Therapy in Chronic Inflammatory Demyelinating Polyneuropathy
Neurol 51:1735-1738, Good,J.L.,et al, 1998

Intravenous Immune Globulin Therapy for Neurologic Diseases
Ann Int Med 126:721-730, Dalakas,M.C., 1997

Cost Effectiveness of Oral Compared with IV Antibiotic Therapy for Pts with Early Lyme Dis or Lyme Arthritis
NEJM 337:357-363, Eckman,M.H.,et al, 1997

Regional Subacute Cranial Neuropathies Following Internal Carotid Cisplatin Infusion
Neurol 47:1088-1090, Alderson,L.M.,et al, 1996

Prolonged Paralysis After Neuromuscular Blockage
Muscle & Nerve, 18:937-94295., Gooch,J., 1995

Plasma Exchange and Intravenous Immunoglobulin Treatment of Neuromuscular Disease
Ann Neurol 35:260-268, Thornton,C.A.&Griggs,R.C., 1994

Toxoplasma Encephalitis in Patients with the Acquired Immunodeficiency Syndrome
Medicine 71:224-239, Renold,C.,et al, 1992

Recurrent Aseptic Meningitis Complicating Intravenous Immunoglobulin Therapy for CIDP
Neurol 42:1636-1637, Vera-Ramirez,M.,et al, 1992

Complete Ophthalmoplegia as a Complication of Acute Corticosteroid-and Pancuronium-Associated Myopathy
Neurol 41:921-922, Sitwell,L.D.,et al, 1991

Postmarketing Surveillance for Neurologic Adverse Events after Hepatitis B Vaccination, Exp of the First 3 Yrs
Am J Epidemiol 127:337-352, Shaw,F.E.,et al, 1988

Vitamin B12 Deficiency:NICE Guideline Summary
BMJ 385:q1019, q1262, Sands,T.,et al, 2024

Phase 2 Trial of Difelikefalin in Notalgia Paresthetica
NEJM 388:511-517, Kin,B.S.,et al, 2023

New-Onset Diplopia and Headache in a Patient with Metastatic Breast Cancer
Neurol 100:927-931, Rizzo,S.A.,et al, 2023

Posterior Reversible Encephalopathy Syndrome
NEJM 388:2171-2178, Geocadin,R.G., 2023

Cannabis-Related Disorders and Toxic Effects
NEJM 389: 2267-2275, Gorelick,D.A., 2023

Neurological Events Reported after COVID-19 Vaccines: An Analysis of Vaccine Adverse Event Reporting System
Ann Neurol 91:756-771, Frontera, J.A.,et al, 2022

A 48-Year-Old Woman with 6 Months of Vivid Visual Hallucinations
Neurol 99:166-171, Kizza, J.,et al, 2022

Chorioretinopathy After Corticosteroid Treatment for Optic Neuritis
Neurol 96:e305-e306, Ling, J. and Micieli, J.A., 2021

Clinical and Radiologic Features of Pedicatric Opioid Use-Associated Neurotoxicity with Cerebellar Edema (POUNCE) Syndrome
Neurol 94:710-712, Kim, D.D. & Prasad, A.N., 2020

Blurred Vision
BMJ 368:m569, Zhou, S.,et al, 2020

Pregabalin and Gabapentin for Pain
BMJ 369:m1315, Mathieson, S.,et al, 2020

Migraine
NEJM 383:1866-1876, Ashina, M., 2020

Looking Beyond the Usual
Delhi J Ophthal doi:7869/djo.555, Shakrawal, J.,et al, 2020

The Dangers of PRES
Neurol 92:e282-e285, Chaterine, C.,et al, 2019

Neuromuscular Adverse Events Associated with Anti-PD-1 Monoclonal Antibodies
Neurol 92:663-674, Johansen, A.,et al, 2019

Association Between Peripheral Neuropathy and Exposure to Oral Fluoroquinolone or Amoxicillin-Clavulanate Therapy
JAMA Neurol 76:827-833, Morales, D.,et al, 2019

Reversible Cerebral Vasoconstriciton Syndrome
www.UptoDate.com, June, Singhal, A., 2019

Maternal and Fetal Risks of Natalizumab Exposure in Utero
Neurol 90:443-444, Marrie, R.A.,et al, 2018

Acute demyelinating polyneuropathy induced by nivolumab
JNNP 89:435-437, Fukumoto, Y.,et al, 2018



Showing articles 0 to 50 of 246 Next >>